Process signatures in glatiramer acetate synthesis: structural and functional relationships

[1]  C. López-Morales,et al.  Design of a strong cation exchange methodology for the evaluation of charge heterogeneity in glatiramer acetate , 2017, Journal of pharmaceutical and biomedical analysis.

[2]  S. Boscardin,et al.  Adjuvants: Classification, Modus Operandi, and Licensing , 2016, Journal of immunology research.

[3]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[4]  M. Miranda-Hernández,et al.  Theoretical approximations and experimental extinction coefficients of biopharmaceuticals , 2016, Analytical and Bioanalytical Chemistry.

[5]  J. Pradines,et al.  Demonstration of equivalence of a generic glatiramer acetate (Glatopa™) , 2015, Journal of the Neurological Sciences.

[6]  M. Miranda-Hernández,et al.  Analysis of therapeutic proteins and peptides using multiangle light scattering coupled to ultra high performance liquid chromatography. , 2015, Journal of separation science.

[7]  D. Crommelin,et al.  Introduction: Defining the Position of Non-Biological Complex Drugs , 2015 .

[8]  Xuesi Chen,et al.  The synthesis, deprotection and properties of poly(γ-benzyl-l-glutamate) , 2013, Science China Chemistry.

[9]  Chris Holloway,et al.  Scientific considerations for complex drugs in light of established and emerging regulatory guidance , 2012, Annals of the New York Academy of Sciences.

[10]  Yongsheng Niu,et al.  Synthesis and Characterization of Poly(L-glutamic acid) with High Molecular Weight , 2012 .

[11]  J. Nicholas.  Complex Drugs and Biologics: Scientific and Regulatory Challenges for Follow-on Products , 2012 .

[12]  Y. Ramot,et al.  Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone®, and TV-5010, Protiramer) in Rats and Monkeys , 2012, Toxicologic pathology.

[13]  A. Heise,et al.  How controlled and versatile is N-carboxy anhydride (NCA) polymerization at 0 °C? Effect of temperature on homo-, block- and graft (co)polymerization , 2010 .

[14]  T. Brenner,et al.  Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy , 2010, Journal of Neuroimmunology.

[15]  D. Ladkani,et al.  The glatiramoid class of immunomodulator drugs. , 2009, Expert opinion on pharmacotherapy.

[16]  M. Trojano,et al.  Glatiramer acetate in multiple sclerosis: a review. , 2007, CNS drug reviews.

[17]  J. Oger,et al.  During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4 , 2006, Journal of Neuroimmunology.

[18]  H. Lassmann,et al.  The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis , 2006, Neurological Sciences.

[19]  M. Sela,et al.  Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy , 2003, Multiple sclerosis.

[20]  Moses Rodriguez,et al.  Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  C. Farina,et al.  Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients , 2002, Journal of Neuroimmunology.

[22]  M. Sela,et al.  Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone® , 2001, Journal of Neuroimmunology.

[23]  C. Nelson,et al.  Structural and Functional Consequences of Altering a Peptide MHC Anchor Residue1 , 2001, The Journal of Immunology.

[24]  R. Hohlfeld,et al.  Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis , 2001, Drug safety.

[25]  M. Schwartz,et al.  T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Hans Lassmann,et al.  Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation? , 1999, The Journal of experimental medicine.

[27]  W. Hennink,et al.  Synthesis and characterization of poly‐L‐lysine with controlled low molecular weight , 1997 .

[28]  T. Deming,et al.  Facile synthesis of block copolypeptides of defined architecture , 1997, Nature.

[29]  T. Deming.  Transition Metal−Amine Initiators for Preparation of Well-Defined Poly(γ-benzyl l-glutamate) , 1997 .

[30]  R. Arnon.  The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. , 1996, Immunology letters.

[31]  P. Allen,et al.  Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. , 1996, Annual review of immunology.

[32]  S. Wassertheil-Smoller,et al.  A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. , 1987, The New England journal of medicine.

[33]  H. Harwood.  Mechanism of N-carboxy anhydride polymerization , 1985 .

[34]  E. Peggion,et al.  α-amino acid N-carboxyanhydride polymerizations - a mechanistic analysis , 1981 .

[35]  C. Frazier.  Citizen petition. , 1980, Annals of allergy.

[36]  A. Meshorer,et al.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. , 1974, Clinical immunology and immunopathology.

[37]  A. Meshorer,et al.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen , 1973, European journal of immunology.

[38]  J. Cowie,et al.  Polymers: Chemistry and Physics of Modern Materials , 1973 .

[39]  A. Meshorer,et al.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide , 1971, European journal of immunology.

[40]  E. Peggion,et al.  Mechanism of N-Carboxyanhydride (NCA) Polymerization in Dioxane. Initiation by Carbon-14-Labeled Amines1 , 1966 .

[41]  P. Y. Paterson.  Experimental allergic encephalomyelitis and autoimmune disease. , 1966, Advances in immunology.

[42]  E. Peggion,et al.  Polymerization of γ‐ethyl‐L‐glutamate‐N‐carboxyanhydride initiated by di‐n‐butyl and di‐isopropyl amine , 1964 .

[43]  E. Blout,et al.  Polypeptides. XV.1Infrared Spectroscopy and the Kinetics of the Synthesis of Polypeptides: Primary Amine Initiated Reactions , 1957 .

[44]  P. Flory.  Molecular Size Distribution in Ethylene Oxide Polymers , 1940 .